Pearls & Oy-sters: An unusual case of varicella-zoster virus cerebellitis and vasculopathy PEARLS 1. CNS complications of varicella-zoster virus (VZV) occur mainly in immunocompromised or elderly patients and include meningitis, myelitis, acute encephalitis, vasculopathy, and, rarely, cerebellitis. CASE REPORT A 67-year-old woman presented with unsteadiness and dizziness of gradual onset. Two weeks before presentation, the patient had a painful vesicular rash at the left ear followed within 9 days by acute left peripheral facial palsy; a diagnosis of Ramsay Hunt syndrome (RHS) was made and oral valacyclovir was started. A few days after initiating valacyclovir, she developed gait instability, which gradually worsened. Her medical history disclosed well-controlled diabetes mellitus and hypertension, and therapy included metformin, ramipril, hydrochlorothiazide, and acetylsalicylic acid. On neurologic examination, the patient was unable to stand and walk unassisted; she had a wide-based gait, predominantly left-sided limb ataxia, and bilateral dysdiadochokinesia. On cranial nerve examination, the patient had a left lower motor neuron facial palsy and had pain in all 3 branches of the left trigeminal nerve. Deep tendon reflexes, strength, and sensation were normal. Head CT displayed hypodensity of the left medial pons, and, because of suspected CNS involvement by VZV, the patient was treated with IV acyclovir (10 mg/kg 3 times daily) for 10 days. Brain MRI, performed the second day of therapy, revealed one lesion in the left pons, one in the left midbrain, and one in the right periventricular area. All 3 lesions were hyperintense on T2 and diffusionweighted imaging sequences and hypointense on apparent diffusion coefficient, consistent with recent ischemic lesions ( figure) . No other supratentorial or cerebellar lesions were seen. Magnetic resonance angiography (MRA) was normal. Absolute lymphocyte count was 550/mL (normal 0.95-4.40) with inversion of the CD41:CD81 T-cell ratio. CSF analysis showed 40 leukocytes/mL (mainly mononuclear cells), 40 erythrocytes/mL, protein 0.46 g/L (normal 0.15-0.45), and glucose 99 mg/dL (normal 45-80). CSF VZV PCR was positive and anti-VZV IgG antibody was detected in the CSF. PCR tests for other neurotropic viruses were negative. Common causes of stroke including atherosclerosis or dissection were excluded. After 2 days of treatment with IV acyclovir, the patient's symptoms improved and at discharge she had no difficulty in standing and walked with unilateral support. Facial pain was treated successfully with carbamazepine 400 mg/day. At the last follow-up 3 months later, the patient walked without support, retained a mild facial weakness, and denied facial pain after she gradually ceased carbamazepine.
CNS complications of varicella-zoster virus (VZV)
occur mainly in immunocompromised or elderly patients and include meningitis, myelitis, acute encephalitis, vasculopathy, and, rarely, cerebellitis. [1] [2] [3] [4] [5] [6] [7] [8] 2. Clinical diagnosis of VZV neurologic disorders is confirmed by virologic analysis with the detection of VZV DNA or anti-VZV immunoglobulin G (IgG) antibody in the CSF. 6, 7 OY-STERS 1. Neurologists should be aware of the possibility of CNS involvement following VZV reactivation even in immunocompetent patients. 2. Antiviral treatment should be started as soon as clinical diagnosis is suspected because therapy can lead to partial or complete resolution of the neurologic deficits.
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CASE REPORT A 67-year-old woman presented with unsteadiness and dizziness of gradual onset. Two weeks before presentation, the patient had a painful vesicular rash at the left ear followed within 9 days by acute left peripheral facial palsy; a diagnosis of Ramsay Hunt syndrome (RHS) was made and oral valacyclovir was started. A few days after initiating valacyclovir, she developed gait instability, which gradually worsened. Her medical history disclosed well-controlled diabetes mellitus and hypertension, and therapy included metformin, ramipril, hydrochlorothiazide, and acetylsalicylic acid. On neurologic examination, the patient was unable to stand and walk unassisted; she had a wide-based gait, predominantly left-sided limb ataxia, and bilateral dysdiadochokinesia. On cranial nerve examination, the patient had a left lower motor neuron facial palsy and had pain in all 3 branches of the left trigeminal nerve. Deep tendon reflexes, strength, and sensation were normal. Head CT displayed hypodensity of the left medial pons, and, because of suspected CNS involvement by VZV, the patient was treated with IV acyclovir (10 mg/kg 3 times daily) for 10 days. Brain MRI, performed the second day of therapy, revealed one lesion in the left pons, one in the left midbrain, and one in the right periventricular area. All 3 lesions were hyperintense on T2 and diffusionweighted imaging sequences and hypointense on apparent diffusion coefficient, consistent with recent ischemic lesions (figure). No other supratentorial or cerebellar lesions were seen. Magnetic resonance angiography (MRA) was normal. Absolute lymphocyte count was 550/mL (normal 0.95-4.40) with inversion of the CD41:CD81 T-cell ratio. CSF analysis showed 40 leukocytes/mL (mainly mononuclear cells), 40 erythrocytes/mL, protein 0.46 g/L (normal 0.15-0.45), and glucose 99 mg/dL (normal 45-80). CSF VZV PCR was positive and anti-VZV IgG antibody was detected in the CSF. PCR tests for other neurotropic viruses were negative. Common causes of stroke including atherosclerosis or dissection were excluded. After 2 days of treatment with IV acyclovir, the patient's symptoms improved and at discharge she had no difficulty in standing and walked with unilateral support. Facial pain was treated successfully with carbamazepine 400 mg/day. At the last follow-up 3 months later, the patient walked without support, retained a mild facial weakness, and denied facial pain after she gradually ceased carbamazepine. DISCUSSION We describe a healthy, immunocompetent adult patient who developed herpes zoster that progressed to cerebellar ataxia and trigeminal neuropathic pain. Brain MRI findings of focal ischemic lesions in the brainstem and right hemisphere are inconsistent with cerebellar involvement, while trigeminal dysfunction presumably results from the lesion in the left pons. Based on 1) the evidence of MRI abnormalities; 2) the detection of VZV DNA and anti-VZV IgG antibody in the CSF; 3) the improvement of symptoms following acyclovir treatment; and 4) the exclusion of alternative cause for acute cerebellar ataxia and stroke, the patient was diagnosed with VZV cerebellitis and multifocal vasculopathy. Therefore, we hypothesize that in our patient the reactivation of VZV from the geniculate ganglion causing RHS was followed by anterograde transaxonal spread of virus through the sensory pathways to both cerebellum and cerebral arteries, causing cerebellitis and trigeminal impairment, respectively. Although the average time from rash to the onset of neurologic symptoms and signs in VZV vasculopathy is typically a few months, they can occur simultaneously or within a week. 6 TIAs and stroke are not uncommon after VZV reactivation in adults even without rash, and vasculopathy is caused by viral infection of the blood vessels. [5] [6] [7] In our patient, MRA did not document any focal narrowing or stenosis in the large and medium cerebral arteries, suggesting that disease exclusively affected small arteries in this patient. Acute cerebellar ataxia as a result of VZV is extremely rare in adults and it has not been reported following herpes zoster. 1 Indeed, 3 adult patients with VZV cerebellitis without a history of rash have been described in the literature. We report a virologically documented case of double CNS complications occurring with VZV reactivation and emphasize the importance of recognizing this neurologic disorder susceptible to improvement with antiviral therapy.
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